Metsera Announces Positive Topline Data From MET-233i Study, Stock Up In Pre-Market

(RTTNews) - Metsera, Inc. (MTSR), Monday announced positive topline data from the Phase 1 clinical trial of MET-233i in participants with overweight or obesity without type 2 diabetes.

The Phase 1 trial involved a total of 80 participants, who were administered single doses from 0.15 mg to 2.4 mg of MET-233i, and multiple doses from 0.15 mg to 1.2 mg of the same given once weekly over five weeks without titration.

The randomized, placebo-controlled, double-blind Phase 1 trial showed upto 8.4 percent mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals.

The company is advancing MET-233i as a monotherapy and in combination with MET-097i, and expects its topline data in late 2025 and by year-end 2025 or early 2026, respectively.

Additionally, the company anticipates topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025.

In the pre-market hours, MTSR is trading at $32.07, up 16.66 percent on the Nasdaq.